AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39486803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacryoendoscopic-assisted laser dacryoplasty with silicone intubation (DLDI)
Number of subjects: 522
Study 39486811 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey-based needs assessment
Number of subjects: 120
Study 39486811 — intervention group
Group type: COMPARATOR
Intervention: Meeting-based needs assessment
Number of subjects: 120
Study 39486818 — intervention group
Group type: EXPERIMENTAL
Intervention: Total B-IPQ score
Number of subjects: 944
Study 39486818 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional representations (emotion and illness concern combined)
Number of subjects: 944
Study 39486818 — intervention group
Group type: EXPERIMENTAL
Intervention: B-IPQ items for consequence, illness concern and emotion
Number of subjects: 944
Study 39486820 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual health communication plus an evidence summary ('fact box')
Number of subjects: 800
Study 39486820 — intervention group
Group type: COMPARATOR
Intervention: Usual health communication
Number of subjects: 800
Study 39486824 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic compression garments (compression class 2 (CCL2): 23-32 mm Hg) plus usual care
Number of subjects: 400
Study 39486824 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 39486833 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy with bile cultures
Number of subjects: 703
Study 39486886 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective HDAC inhibition in combination with immunotherapy (specifics on dosage and duration not available)
Number of subjects: 0
Study 39486886 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab (NCT03419481)
Number of subjects: 0
Study 39486892 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated oxygen administration (AOA) via the O2matic device
Number of subjects: 60
Study 39486892 — intervention group
Group type: COMPARATOR
Intervention: Standard care (manual oxygen administration)
Number of subjects: 60
Study 39486904 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-based cervical screening
Number of subjects: 395725
Study 39486904 — intervention group
Group type: COMPARATOR
Intervention: Cytology-based screening
Number of subjects: 395725
Study 39486904 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-negative at baseline
Number of subjects: 395725
Study 39486904 — intervention group
Group type: COMPARATOR
Intervention: Normal cytology
Number of subjects: 395725
Study 39486904 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-positive with negative cytology triage
Number of subjects: 395725
Study 39486904 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16 or HPV 18-positive with negative cytology triage
Number of subjects: 395725
Study 39487326 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1%-clindamycin 1% combination gel
Number of subjects: 1617
Study 39487326 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1% monotherapy
Number of subjects: 1617
Study 39487326 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin 1% monotherapy
Number of subjects: 1617
Study 39487337 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg cilostazol daily for 7 days
Number of subjects: 57
Study 39487337 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rosuvastatin daily for 7 days
Number of subjects: 57
Study 39487337 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 200 mg cilostazol and 20 mg rosuvastatin daily for 7 days
Number of subjects: 57
Study 39487373 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib (200 mg qd or 175 mg bid) plus Olaparib (200 mg bid)
Number of subjects: 130
Study 39487373 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib plus Olaparib
Number of subjects: 130
Study 39487386 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored patient navigation program (PN-LCNS) for 3 months with phone-based, bilingual support and additional resources.
Number of subjects: 288
Study 39487386 — intervention group
Group type: COMPARATOR
Intervention: Standard patient navigation (control group).
Number of subjects: 288
Study 39487418 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanish (light curable resin-modified glass ionomer varnish)
Number of subjects: 53
Study 39487418 — intervention group
Group type: COMPARATOR
Intervention: Control (fluoride varnish)
Number of subjects: 53
Study 39487428 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self-Determination counselling
Number of subjects: 81
Study 39487428 — intervention group
Group type: COMPARATOR
Intervention: Diet leaflet only (Control)
Number of subjects: 81
Study 39487428 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participation in trial
Number of subjects: 81
Study 39487522 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (5 sessions of 100 minutes each)
Number of subjects: 34
Study 39487522 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 34
Study 39487522 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study 39487711 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-sirolimus (ABI-009) administered IV on days 1 and 8 of cycle 1, in combination with temozolomide (125 mg/m2) and irinotecan.
Number of subjects: 33
Study 39487711 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-sirolimus (ABI-009) at maximum tolerated dose (MTD) of 15 mg/m2.
Number of subjects: 33
Study 39487813 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment-driven referral to rehabilitation services
Number of subjects: 265
Study 39487813 — intervention group
Group type: COMPARATOR
Intervention: No referral to rehabilitation services (control)
Number of subjects: 265
Study 39487818 — intervention group
Group type: EXPERIMENTAL
Intervention: ReSPECT plans
Number of subjects: 842
Study 39487818 — intervention group
Group type: COMPARATOR
Intervention: Standalone 'do not attempt cardiopulmonary resuscitation' forms
Number of subjects: 842
Study 39487824 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty incidence
Number of subjects: 2100000
Study 39487824 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty prevalence
Number of subjects: 2100000
Study 39487824 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to higher frailty state
Number of subjects: 2100000
Study 39487824 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare use and costs
Number of subjects: 2100000
Study 39487824 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation projections
Number of subjects: 2100000
Study 39487824 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario analysis
Number of subjects: 2100000
Study 39487920 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics analysis (performed on 60 patients with discrete tumors)
Number of subjects: 101
Study 39487920 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphomics analysis (performed on all 101 patients)
Number of subjects: 101
Study 39487920 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiomics and morphomics features
Number of subjects: 101
Study 39488138 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal laser treatment (3-6 applications)
Number of subjects: 46
Study 39488138 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor exercises (9-18 sessions)
Number of subjects: 46
Study 39488138 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Vaginal laser and PFE)
Number of subjects: 46
Study 39488216 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg orally twice per day after a 5-day titration period
Number of subjects: 123
Study 39488216 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 123
Study 39488224 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR-guided strategy
Number of subjects: 2000
Study 39488224 — intervention group
Group type: COMPARATOR
Intervention: FFR-guided strategy
Number of subjects: 2000
Study 39488224 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2000
Study 39488229 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care model (group Problem Management Plus and antidepressant therapy)
Number of subjects: 487
Study 39488230 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA)
Number of subjects: 217
Study 39488230 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 217
Study 39488230 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA
Number of subjects: 217
Study 39488255 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypercapnia in COPD patients
Number of subjects: 1526
Study 39488255 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1526
Study 39488333 — intervention group
Group type: EXPERIMENTAL
Intervention: ORIENT diet
Number of subjects: 568
Study 39488412 — intervention group
Group type: EXPERIMENTAL
Intervention: MammoWave AI-based classification algorithm
Number of subjects: 10000
Study 39488412 — intervention group
Group type: COMPARATOR
Intervention: Conventional breast examination path (control)
Number of subjects: 10000
Study 39488424 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised tACS (10 Hz)
Number of subjects: 159
Study 39488424 — intervention group
Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 159
Study 39488424 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised tACS
Number of subjects: 159
Study 39488423 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Built Environment (BE)
Number of subjects: 212
Study 39488423 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessibility to transit station
Number of subjects: 212
Study 39488423 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural barriers in the BE
Number of subjects: 212
Study 39488423 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy (ASES-8)
Number of subjects: 212
Study 39488423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of movement (BFOM)
Number of subjects: 212
Study 39488430 — intervention group
Group type: EXPERIMENTAL
Intervention: ERS+SMS
Number of subjects: 448
Study 39488430 — intervention group
Group type: EXPERIMENTAL
Intervention: ERS only
Number of subjects: 448
Study 39488430 — intervention group
Group type: COMPARATOR
Intervention: SMS/control
Number of subjects: 448
Study 39488485 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontline regimens including cyclophosphamide, thalidomide and dexamethasone; bortezomib, cyclophosphamide and dexamethasone; thalidomide and dexamethasone.
Number of subjects: 943
Study 39488485 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation-ineligible patients (N = 491).
Number of subjects: 943
Study 39488485 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation-eligible patients (N = 452).
Number of subjects: 943
Study 39488485 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with known prognostic factors.
Number of subjects: 943
Study 39488504 — intervention group
Group type: EXPERIMENTAL
Intervention: xanomeline/trospium chloride
Number of subjects: 0
Study 39488504 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 39488538 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood test based on mid-infrared (MIR) metabolic fingerprinting
Number of subjects: 382
Study 39488549 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for genomic high-risk tumors
Number of subjects: 715
Study 39488549 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy for genomic high-risk tumors
Number of subjects: 715
Study 39488549 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy for genomic low-risk tumors
Number of subjects: 715
Study 39488549 — intervention group
Group type: COMPARATOR
Intervention: No endocrine therapy for genomic low-risk tumors
Number of subjects: 715
Study 39488557 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month meditation training
Number of subjects: 90
Study 39488557 — intervention group
Group type: COMPARATOR
Intervention: Non-native language (English) training
Number of subjects: 90
Study 39488677 — intervention group
Group type: EXPERIMENTAL
Intervention: REMS (medium security)
Number of subjects: 604
Study 39488677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low secure places
Number of subjects: 604
Study 39488682 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline insulin
Number of subjects: 218
Study 39488682 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline C-peptide
Number of subjects: 218
Study 39488682 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IRS (Insulin×0.0295 + C-peptide×0.00372)
Number of subjects: 218
Study 39488682 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HbA1c
Number of subjects: 218
Study 39488682 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IRS
Number of subjects: 218
Study 39488777 — intervention group
Group type: EXPERIMENTAL
Intervention: Active H-coil rTMS
Number of subjects: 17
Study 39488777 — intervention group
Group type: COMPARATOR
Intervention: Sham H-coil rTMS
Number of subjects: 17
Study 39488821 — intervention group
Group type: EXPERIMENTAL
Intervention: IcoSema (175 U icodec, 0.5 mg semaglutide)
Number of subjects: 31
Study 39488821 — intervention group
Group type: COMPARATOR
Intervention: Icodec (175 U)
Number of subjects: 31
Study 39488821 — intervention group
Group type: COMPARATOR
Intervention: Semaglutide (0.5 mg)
Number of subjects: 31
Study 39488825 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine; specific dosage and duration not mentioned
Number of subjects: 0
Study 39488941 — intervention group
Group type: EXPERIMENTAL
Intervention: Discomfort intolerance
Number of subjects: 163
Study 39488941 — intervention group
Group type: EXPERIMENTAL
Intervention: Discomfort avoidance
Number of subjects: 163
Study 39489149 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic + digital intervention group
Number of subjects: 900
Study 39489149 — intervention group
Group type: COMPARATOR
Intervention: Clinic-only group
Number of subjects: 900
Study 39489284 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 194
Study 39489284 — intervention group
Group type: COMPARATOR
Intervention: Nonobese group
Number of subjects: 194
Study 39489284 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daily step count
Number of subjects: 194
Study 39489399 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention consisting of five sessions plus four brief check-ins delivered by a Yup'ik Community Health Worker, with modifications to the local store environment to provide sugar-free water enhancers.
Number of subjects: 192
Study 39489399 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control arm with no intervention during the main study period.
Number of subjects: 192
Study 39489541 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoPrism-HNSCC assay in monotherapy cohort (n=62)
Number of subjects: 112
Study 39489541 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoPrism-HNSCC assay in chemo-immunotherapy cohort (n=50)
Number of subjects: 112
Study 39489653 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical-Care Pain Observation Tool (CPOT)
Number of subjects: 725
Study 39489653 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-implementation of CPOT)
Number of subjects: 725
Study 39489747 — intervention group
Group type: EXPERIMENTAL
Intervention: SY-5007
Number of subjects: 122
Study 39489895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg orally twice per day (possible reduction to 100 mg twice per day in case of side-effects or hepatotoxicity) for 12 months.
Number of subjects: 30
Study 39489924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified alkylating chemotherapy (IACT)
Number of subjects: 75
Study 39489924 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy (CDCT)
Number of subjects: 75
Study 39489935 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype 2 (28%) with nociplastic pain characteristics
Number of subjects: 217
Study 39489935 — intervention group
Group type: COMPARATOR
Intervention: Phenotype 1 (72%)
Number of subjects: 217
Study 39490766 — intervention group
Group type: EXPERIMENTAL
Intervention: QuitBot
Number of subjects: 760
Study 39490766 — intervention group
Group type: COMPARATOR
Intervention: Smokefree TXT (SFT)
Number of subjects: 760
Study 39490799 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple-fortified salt (QFS)
Number of subjects: 77
Study 39490799 — intervention group
Group type: COMPARATOR
Intervention: Double-fortified salt (DFS)
Number of subjects: 77
Study 39490799 — intervention group
Group type: COMPARATOR
Intervention: Iodized salt
Number of subjects: 77
Study 39490799 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt type (QFS, DFS, iodized salt)
Number of subjects: 77
Study 39490799 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention period
Number of subjects: 77
Study 39490969 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum antiglycopeptidolipid core IgA antibody test
Number of subjects: 282
Study 39490971 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Medical Research Council (mMRC) scale
Number of subjects: 318
Study 39490971 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT)
Number of subjects: 318
Study 39490971 — intervention group
Group type: COMPARATOR
Intervention: Incremental cardiopulmonary cycle exercise testing (CPET)
Number of subjects: 318
Study 39490985 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension-avoidance strategy (target intraoperative MAP 80 mm Hg or over, hold renin-angiotensin-aldosterone system inhibitors on day of surgery and for two days after)
Number of subjects: 7307
Study 39490985 — intervention group
Group type: COMPARATOR
Intervention: Hypertension-avoidance strategy (target intraoperative MAP 60 mm Hg or more, continue all antihypertensives before and after surgery)
Number of subjects: 7307
Study 39491057 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 23
Study 39491057 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (females)
Number of subjects: 23
Study 39491057 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study 39491310 — intervention group
Group type: EXPERIMENTAL
Intervention: ERT16 (16-session emotion regulation therapy)
Number of subjects: 72
Study 39491310 — intervention group
Group type: COMPARATOR
Intervention: ERT8 (8-session emotion regulation therapy)
Number of subjects: 72
Study 39491396 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg twice daily
Number of subjects: 1509
Study 39491396 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg twice daily (adjusted for crossover)
Number of subjects: 1509
Study 39491396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1509
Study 39491572 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy with the ClotTriever System
Number of subjects: 300
Study 39491572 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 300
Study 39491599 — intervention group
Group type: EXPERIMENTAL
Intervention: Phage therapy (172 pharmaceutical phage cocktails targeting Staphylococcus aureus and/or Pseudomonas aeruginosa; 57 for local injection and 99 for intravenous injection)
Number of subjects: 33
Study 39491599 — intervention group
Group type: EXPERIMENTAL
Intervention: Phage therapy
Number of subjects: 33
Study 39491719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet photography, MC1R genetic testing, and action planning (each with two levels: yes v. no)
Number of subjects: 528
Study 39491831 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva samples from periodontitis patients
Number of subjects: 18
Study 39491831 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva samples from CRC patients
Number of subjects: 18
Study 39491831 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC resection material from CRC patients
Number of subjects: 18
Study 39491870 — intervention group
Group type: EXPERIMENTAL
Intervention: Early DOAC initiation (≤4 days from stroke symptom onset)
Number of subjects: 3621
Study 39491870 — intervention group
Group type: COMPARATOR
Intervention: Delayed DOAC initiation (7-14 days)
Number of subjects: 3621
Study 39491902 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial focused ultrasound (tfUS) targeting the right amygdala, 10-min sessions, 8 weekly sessions
Number of subjects: 25
Study 39491945 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam nasal spray (MDZ-NS) 5 mg administered for seizure clusters, with a second 5 mg dose possible if seizures did not terminate within 10 min or recurred within 10 min-6 h.
Number of subjects: 161
Study 39492050 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus Abiraterone
Number of subjects: 0
Study 39492050 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Abiraterone
Number of subjects: 0
Study 39492125 — intervention group
Group type: EXPERIMENTAL
Intervention: PIFU and asynchronous telemedicine
Number of subjects: 200
Study 39492125 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 39492363 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL) as adjunctive treatment in coronary angioplasty
Number of subjects: 500
Study 39492485 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer fasting durations
Number of subjects: 95
Study 39492485 — intervention group
Group type: EXPERIMENTAL
Intervention: Early morning food consumption
Number of subjects: 95
Study 39492655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application follow-up
Number of subjects: 80
Study 39492702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin DES
Number of subjects: 1367
Study 39492702 — intervention group
Group type: COMPARATOR
Intervention: Thin-strut DES
Number of subjects: 1367
Study 39492703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SCB)
Number of subjects: 70
Study 39492703 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-coated balloon (PCB)
Number of subjects: 70
Study 39492701 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored antiplatelet therapy (early escalation with low-dose ticagrelor at 60 mg twice daily plus aspirin for <6 months, followed by late de-escalation to clopidogrel monotherapy for >6 months)
Number of subjects: 0